Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

- Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)

Currently, value stocks are mostly value traps, while market leaders are expensive. We have to find diversification elsewhere. Genome editing is a space poised for innovation. The costs are decreasing while its effects spill over to various sectors.

Crispr Is Getting A Foot In The Door, And Maybe Investors Should Too

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m. ET to review clinical data presented during the Plenary Scientific Session at the annual ASH Meeting and Exposition from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with sickle cell disease and beta thalassemia. The presentation will include speakers from Vertex and CRISPR Therapeutics as well as Haydar Frangoul M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcare's TriStar Centennial Medical Center, and a principal investigator in the CTX001 clinical studies.

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th

Allogene Therapeutics Inc

Atara Biotherapeutics

Bristol-Myers

Cellectis SA

Gilead Sciences

Novartis

Pfizer

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.

Regenerative Medicines: Universal Cell Therapy Gaining Momentum

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.

Is Gene Editing Already Leaving CRISPR Therapeutics Behind?

Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock. The post Volatility May Continue, But CRISPR Stock Remains a Buy appeared first on InvestorPlace.

Volatility May Continue, But CRISPR Stock Remains a Buy

This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments. The post Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-Hold Biotech Play appeared first on InvestorPlace.

Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-Hold Biotech Play

Despite a large 3x rise since the March 23 lows of this year, at the current price of around $107 per share we believe CRISPR Therapeutics stock, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has more room for growth in the near term.

Here's Why You Should Stay Invested In CRISPR Stock Despite The Recent 3x Rally

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, November 19, 2020, at 12:00 p.m. ET.

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

Intra-Cellular Therapies

Innovation might be worth the high risk up front investment.

Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs

Crispr Therapeutics and Vertex Pharmaceuticals unveiled promising results for a gene-editing approach to blood diseases Wednesday. The news sent CRSP stock flying higher.

Why This Gene-Editing Player Just Outpaced Bullish Biotech Stocks

Vertex Pharmaceuticals

CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.

CRISPR and Vertex Release Additional Data for Blood Disease Treatment

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies has been accepted for an oral presentation during the Plenary Scientific Session at the annual ASH Meeting and Exposition, which will take place virtually from December 5-8, 2020. Haydar Frangoul, M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcare's TriStar Centennial Medical Center, will deliver the presentation on behalf of all the authors on December 6, 2020.

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Its approach to cell therapy is lucrative and immensely powerful for patients.

Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode

Arrowhead Pharmaceuticals

These biotechs are fueling up for massive market launches.

2 Monster Young Biotech Stocks to Add to Your Watchlist

The company flipped to a bottom-line loss for the period.

CRISPR Therapeutics Stock Falls 3.5% on Q3 Results

-Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

Apple

Citrix Systems

MercadoLibre

PayPal

Seagen

Tesla

Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.

7 Strong Nasdaq Stocks to Buy As They Keep Marching Higher

Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.

Is CRISPR Therapeutics a Good Biotech Stock to Buy Now?

One analyst goes contrarian, raising her price target on the stock following some very dispiriting news from the company.

Is CRISPR Therapeutics Really Headed to $110?

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

The death of a clinical trial participant overshadowed clear signs of efficacy for the company's off-the-shelf cellular therapy for non-Hodgkin lymphoma.

CRISPR Therapeutics Reports Mixed Cancer Trial Results

A patient death in an early stage cancer trial is unnerving investors.

News for CRISPR Therapeutics Stock (CRSP)